Evidence map›Paper›PMID 29720260›Full record

ArticleArthritis research & therapy2018

Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis.

Emil Rydell, Kristina Forslind, Jan-Åke Nilsson, Lennart T H Jacobsson, Carl Turesson

Abstract read
In one paragraph

Article in Arthritis research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Autoantibodies as prognostic markers in rheumatoid arthritis.Journal of translational autoimmunity · 2025
    Review
  11. Article
  12. Age of onset of rheumatoid arthritis and radiographic changes.Seminars in arthritis and rheumatism · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Emil RydellRheumatology, Department of Clinical Sciences, Malmö, Lund University, Jan Waldenströms gata 35, SE-202 13, Malmö, Sweden. emil.rydell@med.lu.se.ORCID 0000-0002-3643-7648
Kristina ForslindDepartment of Research and Education, Helsingborg Hospital, Charlotte Yhlens gata 10, SE-251 87, Helsingborg, Sweden.
Jan-Åke NilssonRheumatology, Department of Clinical Sciences, Malmö, Lund University, Jan Waldenströms gata 35, SE-202 13, Malmö, Sweden.
Lennart T H JacobssonRheumatology, Department of Clinical Sciences, Malmö, Lund University, Jan Waldenströms gata 35, SE-202 13, Malmö, Sweden.
Carl TuressonRheumatology, Department of Clinical Sciences, Malmö, Lund University, Jan Waldenströms gata 35, SE-202 13, Malmö, Sweden.

Funding

Lunds Universitet ALFSKANE-446501Reumatikerförbundet R-481821Vetenskapsrådet 2015-02228
6 · The paper itself

Abstract

backgroundIdentification of risk factors for rapid joint destruction in early rheumatoid arthritis (RA) can be helpful for optimizing treatment, and improving our understanding of destructive arthritis and its mechanisms. The objective of this study was to investigate the relationship between early RA patient characteristics and subsequent rapid radiographic progression (RRP).

methodsAn inception cohort of patients with early RA (symptom duration < 12 months), recruited during 1995-2005 from a defined area (Malmö, Sweden), was investigated. Radiographs of the hands and feet were scored in chronological order according to the modified Sharp-van der Heijde score (SHS), by a trained reader. RRP was defined as an increase of ≥ 5 points in SHS per year.

resultsTwo hundred and thirty-three patients were included. Radiographs were available from 216 patients at baseline, 206 patients at 1 year, and 171 patients at 5 years. Thirty-six patients (22%) had RRP up to 5 years. In logistic regression models, rheumatoid factor (RF) and anti-cyclic citrullinated peptides (anti-CCP), and increased erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) at baseline, predicted RRP over 5 years. Patients identified as overweight or obese had a significantly reduced risk of RRP up to 5 years (odds ratio (OR) 0.26; 95% confidence interval (CI) 0.11-0.63; adjusted for RF, baseline erosions, and ESR). Similar point estimates were obtained when stratifying for antibody status, and in models adjusted for smoking. A history of ever smoking was associated with a significantly increased risk of RRP up to 5 years, independent of body mass index (BMI) (OR 3.17; 95% CI 1.22-8.28; adjusted for BMI). At the 1-year follow-up, erosive changes, Disease Activity Score of 28 joints, Health Assessment Questionnaire, swollen joint count, and patient's global assessment of disease activity and pain were also significantly associated with RRP up to 5 years.

conclusionsA history of smoking, presence of RF and/or anti-CCP and early erosions, high initial disease activity and active disease at 1 year, all increase the risk of RRP. Patients with a high BMI may have a reduced risk of severe joint damage. This pattern was not explained by differences in disease activity or antibody status. The results of this study suggest independent effects of smoking and BMI on the risk of RRP.

Indexed as

Body Mass IndexSeverity of Illness IndexSmokingAgedArthritis, RheumatoidAutoantibodiesC-Reactive ProteinDisease ProgressionFemaleHumansMaleMiddle AgedRadiographyRheumatoid FactorSwedenAutoantibodiesC-Reactive ProteinRheumatoid FactorBody mass indexDisease activityJoint damageRadiographic progressionRheumatoid arthritisSmoking

Identifiers

PMID29720260
PMCPMC5932864

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.